Vmn2r51 Inhibitors
Vmn2r51 can affect the receptor's function through various mechanisms that involve the modulation of neurotransmission in the olfactory system. Bicuculline can inhibit Vmn2r51 by antagonizing GABA_A receptors, leading to disrupted GABAergic neurotransmission, which is an essential modulator of signal cascades that involve vomeronasal receptors. Similarly, Tetrodotoxin exerts its inhibitory effect by blocking sodium channels, crucial for action potential generation and propagation in neurons, including those expressing Vmn2r51. This blockade effectively silences the neuronal activity required for Vmn2r51-mediated signal transduction. CNQX and NBQX, both AMPA receptor antagonists, reduce excitatory neurotransmission in the olfactory bulb, thereby diminishing the activation of neural pathways in which Vmn2r51 is involved. D-AP5, targeting the NMDA receptors, further contributes to the reduction of excitatory neurotransmission necessary for Vmn2r51 function.
Chemical inhibitors operate by targeting different aspects of the signaling machinery within the olfactory system. Ondansetron, a 5-HT3 receptor antagonist, and Ketanserin, targeting the 5-HT2A receptors, reduce serotonergic signaling, which can influence the activity of Vmn2r51. Hexamethonium and Methyllycaconitine, both cholinergic antagonists, inhibit Vmn2r51 by decreasing cholinergic input to the olfactory system. Rimonabant, by antagonizing cannabinoid receptor 1, modulates the endocannabinoid system, which interacts with olfactory processes and can lead to decreased activation of Vmn2r51. LY341495, which targets metabotropic glutamate receptors 2/3, reduces glutamatergic neurotransmission, thereby potentially diminishing the receptor's functional activity. Lastly, Yohimbine, an alpha2-adrenergic receptor antagonist, reduces noradrenergic signaling, which can alter the neurotransmitter balance and decrease the functional response of Vmn2r51 to pheromonal cues. Each chemical, through its unique receptor target, contributes to the collective inhibition of Vmn2r51 by modifying the neural activity and neurotransmitter dynamics within the olfactory circuits.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(+)-Bicuculline | 485-49-4 | sc-202498 sc-202498A | 50 mg 250 mg | $82.00 $281.00 | ||
Bicuculline, a GABA_A receptor antagonist, can inhibit Vmn2r51 by disrupting GABAergic neurotransmission, which is an upstream modulator of signal cascades involving vomeronasal receptors, leading to reduced neuronal activity and thereby functionally inhibiting the response of Vmn2r51 in olfactory sensory neurons. | ||||||
6-Cyano-7-nitroquinoxaline-2,3-dione | 115066-14-3 | sc-505104 | 10 mg | $208.00 | 2 | |
CNQX acts as an AMPA receptor antagonist and can inhibit Vmn2r51 by decreasing excitatory neurotransmission in the olfactory bulb, which could reduce the activation of pathways that involve Vmn2r51 in the processing of pheromonal signals. | ||||||
Ondansetron | 99614-02-5 | sc-201127 sc-201127A | 10 mg 50 mg | $82.00 $333.00 | 1 | |
Ondansetron, a 5-HT3 receptor antagonist, could inhibit Vmn2r51 by reducing serotonin-mediated excitatory signaling in the olfactory bulb, which might influence the neural circuits that Vmn2r51 is a part of, leading to a downregulation of its functional response to stimuli. | ||||||
Hexamethonium bromide | 55-97-0 | sc-205712 sc-205712A | 10 g 25 g | $46.00 $64.00 | ||
Hexamethonium is a nicotinic acetylcholine receptor antagonist that can inhibit Vmn2r51 by reducing cholinergic input to the olfactory system, which could impact the activity of neurons expressing Vmn2r51, decreasing the functional response to pheromonal cues. | ||||||
Rimonabant | 168273-06-1 | sc-205491 sc-205491A | 5 mg 10 mg | $73.00 $163.00 | 15 | |
Rimonabant, a cannabinoid receptor 1 (CB1) antagonist, can inhibit Vmn2r51 by modulating the endocannabinoid system, which is known to interact with olfactory processes, potentially leading to decreased activation of Vmn2r51 in response to binding of its ligands within the vomeronasal system. | ||||||
LY 341495 | 201943-63-7 | sc-361244 sc-361244A | 1 mg 10 mg | $89.00 $223.00 | 1 | |
LY341495, a metabotropic glutamate receptor 2/3 antagonist, can inhibit Vmn2r51 by reducing glutamatergic neurotransmission, which might reduce the excitatory drive on neurons that express Vmn2r51, thereby diminishing the receptor's functional activity in the vomeronasal system. | ||||||
6-Nitro-7-sulfamoylbenzo[f]quinoxaline-2,3-Dione | 118876-58-7 | sc-478080 | 5 mg | $70.00 | 1 | |
NBQX, another AMPA receptor antagonist, can inhibit Vmn2r51 by reducing glutamatergic excitatory input to the olfactory bulb and associated neural circuits where Vmn2r51 is active, ultimately leading to a decrease in the functional response of this receptor to its specific stimuli. | ||||||
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $51.00 $171.00 $530.00 | 2 | |
Yohimbine, an alpha2-adrenergic receptor antagonist, can inhibit Vmn2r51 by decreasing noradrenergic signaling, which could alter the neurotransmitter balance in olfactory regions where Vmn2r51 operates, resulting in a functional inhibition of the receptor's activity in response to pheromonal detection. | ||||||
Ketanserin | 74050-98-9 | sc-279249 | 1 g | $700.00 | ||
Ketanserin, a 5-HT2A serotonin receptor antagonist, can inhibit Vmn2r51 by reducing serotonergic signaling within the olfactory system, which may influence the signal processing pathways that Vmn2r51 is involved with, leading to a decrease in the functional response of this receptor when it encounters specific chemical signals in the vomeronasal organ. | ||||||